Refine
Year of publication
Has Fulltext
- yes (1224)
Is part of the Bibliography
- no (1224)
Keywords
- Heavy Ion Experiments (21)
- Hadron-Hadron scattering (experiments) (12)
- Hadron-Hadron Scattering (11)
- LHC (9)
- Heavy-ion collision (6)
- Heavy-ion collisions (5)
- Seizure (5)
- ALICE experiment (4)
- Collective Flow (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- Diffraction (3)
- Epilepsy (3)
- Heavy Ions (3)
- Heavy Quark Production (3)
- Jets and Jet Substructure (3)
- pp collisions (3)
- Beam Energy Scan (2)
- Beauty production (2)
- Charm physics (2)
- Chiral Magnetic Effect (2)
- Collectivity (2)
- Corona (2)
- Correlation (2)
- Costs (2)
- Elastic scattering (2)
- Elliptic flow (2)
- Epileptischer Anfall (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Genetics (2)
- Germany (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Pandemic (2)
- Pandemie (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- QCD (2)
- Quarkonium (2)
- SARS-CoV‑2 (2)
- Shear viscosity (2)
- Single electrons (2)
- Status epilepticus (2)
- classical Hodgkin lymphoma (2)
- epilepsy (2)
- immunotherapy (2)
- 900 GeV (1)
- ALICE detector (1)
- Angiomyolipoma (1)
- Anti-nuclei (1)
- Anti-seizure medication (1)
- Anticonvulsant (1)
- B-cell transcription factors (1)
- B-slope (1)
- Bacteriophages (1)
- Beam energy scan (1)
- Beskid Niski Mts (1)
- Biophysical chemistry (1)
- Boosted Jets (1)
- Brain tumor (1)
- COVID-19 (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charged-particle multiplicity (1)
- Charm quark spatial diffusion coefficient (1)
- Chiral magnetic effect (1)
- Coalescence (1)
- Cold nuclear matter effects (1)
- Collective Flow, (1)
- Comparison with QCD (1)
- Covid19-nmr (1)
- Critical point (1)
- DNA methylation (1)
- Data sharing (1)
- Depression (1)
- Deuteron production (1)
- Di-hadron correlations (1)
- EWSR1 (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Ethiopia (1)
- Everolimus (1)
- FGFR (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Forward physics (1)
- Gene fusion (1)
- Groomed jet radius (1)
- HBT (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-Ion Collision (1)
- Heavy-flavor decay electron (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Higher moments (1)
- Immunogenetics (1)
- Immunology (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Interference fragmentation function (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- J/ψ suppression (1)
- Jet Physics (1)
- Jet Substructure (1)
- Jet substructure (1)
- Lafora disease (1)
- MN1 (1)
- MTOR inhibitor (1)
- Material budget (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multiple parton interactions (1)
- NF-κB (1)
- NMR spectroscopy (1)
- Neural network (1)
- Neuroepithelial (1)
- Neurooncology (1)
- Nuclear modification factor (1)
- PATZ1 (1)
- PD-L1 (1)
- PYTHIA (1)
- Particle and Resonance Production (1)
- Pb–Pb (1)
- Pediatric (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Proton-proton collisions (1)
- Proton–proton (1)
- Proton–proton collisions (1)
- Psychiatric disorders (1)
- Quality of life (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- RHIC (1)
- RNA (1)
- Rapidity Range (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Resolution Parameter (1)
- Rhabdomyoma (1)
- SARS-CoV-2 (1)
- STAR (1)
- Single muons (1)
- Sociodemographic characteristics (1)
- SoftDrop (1)
- Splitting function (1)
- Subependymal giant cell astrocytoma (1)
- Systematic Uncertainty (1)
- TR (1)
- TSC (1)
- Thermal model (1)
- Tigray (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Transversity (1)
- Trigger (1)
- Vector Boson Production (1)
- Xenon-based gas mixture (1)
- aftercare structures (1)
- alteplase (1)
- anticonvulsants (1)
- brain metastases (1)
- cHL (1)
- cerebral pseudoprogression (1)
- chronic kidney disease (1)
- cluttering (1)
- complication (1)
- dE/dx (1)
- detector (1)
- diabetic nephropathy (1)
- endovascular thrombectomy (1)
- epidemiology (1)
- epigenetic (1)
- epileptic encephalopathies (1)
- experimental results (1)
- fibroblasts (1)
- fragment screening (1)
- gene expression analysis (1)
- genetics (1)
- global change (1)
- habitat destruction (1)
- healthcare systems (1)
- heavy ion experiments (1)
- heavy-ion collisions (1)
- high-fat-diet (1)
- honey bee classification (1)
- immune checkpoint inhibitor (ICI) (1)
- immune checkpoint inhibitors (ICI) (1)
- immune related adverse events (irAE) (1)
- immunohistochemistry (1)
- infection (1)
- inpatient hospital admissions (1)
- juvenile myoclonic epilepsy (1)
- land use (1)
- leptin receptor-deficient mouse (1)
- levetiracetam (1)
- lichen diversity (1)
- lichenized fungi (1)
- liver (1)
- liver transplantation (1)
- liver transplantation center (1)
- lockdown (1)
- long-term outcome (1)
- loss of B-cell phenotype (1)
- lungs (1)
- luteolin (1)
- mTOR inhibitor (1)
- mechanical recanalization (1)
- medical informatics initiative (1)
- metabolomics (1)
- methylation profiling (1)
- miRNA (1)
- microRNA (1)
- microdissection (1)
- mir-148a (1)
- morbidity (1)
- mtDNA haplotypes (1)
- myxomycete (1)
- neurocritical care (1)
- neurological complication (1)
- neurological side effects (1)
- new records (1)
- nodular sclerosis (1)
- p+p collisions (1)
- pandemic (1)
- pharmacoresistance (1)
- post-liver transplantation management (1)
- prediabetes and type 2 diabetes (1)
- progressive myoclonus epilepsy (1)
- quark gluon plasma (1)
- rare species (1)
- reduced kidney function (1)
- saprotrophic fungi (1)
- secondary data analysis (1)
- seizure (1)
- spectra (1)
- stuttering (1)
- thrombolysis (1)
- tyrosine kinase inhibitor (TKI) (1)
- university hospitals (1)
- wing geometric morphometrics (1)
- Υ suppression (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1085)
- Frankfurt Institute for Advanced Studies (FIAS) (1056)
- Informatik (924)
- Medizin (30)
- Biodiversität und Klima Forschungszentrum (BiK-F) (3)
- Biowissenschaften (3)
- Geowissenschaften / Geographie (3)
- Informatik und Mathematik (3)
- Hochschulrechenzentrum (2)
- Institut für Ökologie, Evolution und Diversität (2)
Background: The approval of everolimus (EVE) for the treatment of angiomyolipoma (2013), subependymal giant cell astrocytoma (2013) and drug-refractory epilepsy (2017) in patients with tuberous sclerosis complex (TSC) represents the first disease-modifying treatment option available for this rare and complex genetic disorder. Objective: The objective of this study was to analyse the use, efficacy, tolerability and treatment retention of EVE in patients with TSC in Germany from the patient’s perspective. Methods: A structured cross-age survey was conducted at 26 specialised TSC centres in Germany and by the German TSC patient advocacy group between February and July 2019, enrolling children, adolescents and adult patients with TSC. Results: Of 365 participants, 36.7% (n = 134) reported the current or past intake of EVE, including 31.5% (n = 115) who were taking EVE at study entry. The mean EVE dosage was 6.1 ± 2.9 mg/m2 (median: 5.6 mg/m2, range 2.0–15.1 mg/m2) in children and adolescents and 4 ± 2.1 mg/m2 (median: 3.7 mg/m2, range 0.8–10.1 mg/m2) in adult patients. An early diagnosis of TSC, the presence of angiomyolipoma, drug-refractory epilepsy, neuropsychiatric manifestations, subependymal giant cell astrocytoma, cardiac rhabdomyoma and overall multi-organ involvement were associated with the use of EVE as a disease-modifying treatment. The reported efficacy was 64.0% for angiomyolipoma (75% in adult patients), 66.2% for drug-refractory epilepsy, and 54.4% for subependymal giant cell astrocytoma. The overall retention rate for EVE was 85.8%. The retention rates after 12 months of EVE therapy were higher among adults (93.7%) than among children and adolescents (88.7%; 90.5% vs 77.4% after 24 months; 87.3% vs 77.4% after 36 months). Tolerability was acceptable, with 70.9% of patients overall reporting adverse events, including stomatitis (47.0%), acne-like rash (7.7%), increased susceptibility to common infections and lymphoedema (each 6.0%), which were the most frequently reported symptoms. With a total score of 41.7 compared with 36.8 among patients not taking EVE, patients currently being treated with EVE showed an increased Liverpool Adverse Event Profile. Noticeable deviations in the sub-items ‘tiredness’, ‘skin problems’ and ‘mouth/gum problems’, which are likely related to EVE-typical adverse effects, were more frequently reported among patients taking EVE. Conclusions: From the patients’ perspective, EVE is an effective and relatively well-tolerated disease-modifying treatment option for children, adolescents and adults with TSC, associated with a high long-term retention rate that can be individually considered for each patient. Everolimus therapy should ideally be supervised by a centre experienced in the use of mechanistic target of rapamycin inhibitors, and adverse effects should be monitored on a regular basis.
Objective: To evaluate the efficacy and tolerability of brivaracetam (BRV) in a severely drug refractory cohort of patients with epileptic encephalopathies (EE).
Method: A multicenter, retrospective cohort study recruiting all patients treated with EE who began treatment with BRV in an enrolling epilepsy center between 2016 and 2017.
Results: Forty-four patients (27 male [61%], mean age 29 years, range 6 to 62) were treated with BRV. The retention rate was 65% at 3 months, 52% at 6 months and 41% at 12 months. A mean retention time of 5 months resulted in a cumulative exposure to BRV of 310 months. Three patients were seizure free during the baseline. At 3 months, 20 (45%, 20/44 as per intention-to-treat analysis considering all patients that started BRV including three who were seizure free during baseline) were either seizure free (n = 4; 9%, three of them already seizure-free at baseline) or reported at least 25% (n = 4; 9%) or 50% (n = 12; 27%) reduction in seizures. An increase in seizure frequency was reported in two (5%) patients, while there was no change in the seizure frequency of the other patients. A 50% long-term responder rate was apparent in 19 patients (43%), with two (5%) free from seizures for more than six months and in nine patients (20%, with one [2 %] free from seizures) for more than 12 months. Treatment-emergent adverse events were predominantly of psychobehavioural nature and were observed in 16%.
Significance: In this retrospective analysis the rate of patients with a 50% seizure reduction under BRV proofed to be similar to those seen in regulatory trials for focal epilepsies. BRV appears to be safe and relatively well tolerated in EE and might be considered in patients with psychobehavioral adverse events while on levetiracetam.
Purpose: Seizures pose a significant burden in patients with primary and secondary brain tumors during the end-of-life period. A wide range of 6 to 56% of clinically observed epileptic seizures at the end of life has been reported. We aimed to analyse the incidence of epileptic seizures at the end of life in brain tumor patients more accurately using not only clinical but also electrophysiological findings.
Methods: This retrospective, single center study included brain tumor patients who died during the stay on the ward or within 7 days after discharge between 01/2015 and 08/2020. Clinical observation of seizures derived from the original medical records and EEG findings (within 45 days prior to death) were analyzed to determine the incidence of seizures in that period.
Results: Of the 68 eligible patients, 50 patients (73.5%) suffered from seizures within 45 days prior to death, of which n = 24 had a status epilepticus. The diagnosis of seizures/ status epilepticus was determined either by the presentation of clinical signs in 45 patients and if not, by the detection of a (possible) non-convulsive status epilepticus in the EEG of five patients.
Conclusion: In the presence of neurologically trained staff and with the frequent use of routine EEG, we were able to identify seizures and to distinguish status epilepticus from encephalopathy/ hypoactive delirium. We detected a higher incidence of seizures and status epilepticus at the end of life in neurooncological patients than previously reported.
The Board of Directors of the German Society of Epileptology and the committee on epilepsy and syncope of the German Society of Neurology have reviewed the current data on vaccination to prevent coronavirus disease 2019 (COVID-19) and vaccination prioritization in people with epilepsy and provide a summary and recommendations.